Ireland Senate Passes Bill to Raise Legal Age for Tobacco Sales to 21

Nov.08.2024
Ireland Senate Passes Bill to Raise Legal Age for Tobacco Sales to 21
The Irish Senate has passed the Public Health (Tobacco) (Amendment) Bill, raising the legal minimum age for the sale of tobacco products to 21.

According to Irish Central, on November 7th, the Irish Senate passed the Public Health (Tobacco) (Amendment) Bill for 2024, completing its legislative process in both houses of parliament. The bill will raise the minimum legal age for the sale of tobacco products to 21. The bill is now set to be submitted to the President for review and signing.

 

After the president signs, the law will take effect on February 1, 2028. The transition period before this is designed to ensure individuals currently aged between 18 and 21 who are eligible to purchase tobacco will not be affected.

 

The bill stipulates that current penalties will be expanded to include punishments for selling tobacco products to individuals under the age of 21. First-time offenders can be fined up to a maximum of 4000 euros or face six months in prison, or both.

 

Ireland's Department of Health said that this measure aims to accelerate the decline in adult smoking prevalence, which have remained at 18% for many years, and reduce child smoking rates to zero. 

 

If the bill is passed, Ireland will become the first country in the European Union to raise the legal age for tobacco sales to 21.

 

"Ireland has long been a world leader in tackling smoking, beginning with the workplace smoking ban in 2004 and continuing with a range of measures including restrictions around the sale, advertising and packaging of smoking products to make them less attractive and less available to young people," Ireland's Minister for Health Stephen Donnelly said.

 

"I look forward to seeing this measure enacted, to help our young people to avoid the lifetime of addiction and illness that tobacco smoking brings," he said.

 

Minister of State Colm Burke, responsible for public health and national drug strategy, said: "This measure will protect our young people from starting their adult lives with an addiction to a product that causes 76% of lung cancers here and kills half of those who use it.

 

"I have strongly supported its introduction from the beginning and I look forward to its enactment."

 

Ireland's Chief Medical Officer, Professor Mary Hogan, said: "The enactment of this legislation represents another significant step in our efforts to reduce smoking levels."

 

"Tobacco smoking continues to be the biggest risk factor driving disability and death combined in our country, placing a huge burden on our health service."

 

"This measure will contribute to eliminating that ongoing threat and will support people to follow healthier behaviours."

 

In December 2023, Donnelly commenced section 28 of the Public Health (Tobacco Products and Nicotine Inhaling Products) Act to prohibit the sale of nicotine-inhaling products such as e-cigarettes (commonly referred to as vapes) to persons under 18.

 

In May 2024, Donnelly implemented parts of the bill that banned the sale of tobacco and nicotine inhalation products through vending machines. In December, he signed a law imposing on-the-spot fines of 2,000 euros for the sale of such products to children. 

 

In addition, Northern Ireland Health Minister Mike Nesbitt has welcomed the introduction of the Tobacco and Vapes Bill at Westminster this week. The bill prohibits anyone born on or after January 1, 2009 will never be able to legally be sold cigarettes, but its implementation in Northern Ireland will be subject to the agreement of the NI Executive and support of the NI Assembly.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Research | Swedish Study Finds Oral Lesions in 79% of Examined Nicotine Pouch Users, With Distinct Tissue Responses
Research | Swedish Study Finds Oral Lesions in 79% of Examined Nicotine Pouch Users, With Distinct Tissue Responses
A new Swedish study found oral mucosal lesions in 79% of examined nicotine pouch users and 89% of tobacco-derived snus users, with different tissue-response patterns between the two categories. For manufacturers and regulators, the findings shift attention toward product formulation, flavouring, pouch materials and local oral exposure, not only whether a product contains tobacco. The study found no higher prevalence of caries or periodontal disease, but it could not establish causality, long-term outcomes or differences between individual products or designs.
Special Report
Jul.27
PMI Q2 Revenue Rises 10.4% as IQOS and VEEV Expand, U.S. ZYN Growth Slows
PMI Q2 Revenue Rises 10.4% as IQOS and VEEV Expand, U.S. ZYN Growth Slows
Philip Morris International’s second-quarter net revenues rose 10.4% to a record $11.19 billion, as heated tobacco and e-vapor expanded across international markets. IQOS remained the main smoke-free growth engine, while VEEV shipments jumped 55.1%. In the United States, however, ZYN shipments increased just 1.8% and consumer offtake was broadly flat to slightly higher. Cigarette volumes also rose, showing that PMI’s transformation is advancing, but growth is becoming increasingly uneven across categories and markets.
PMI
Jul.22
UK Proposes Stricter Vape Packaging Rules as Retailers Warn of £330 Million Impact
UK Proposes Stricter Vape Packaging Rules as Retailers Warn of £330 Million Impact
The UK government has launched a nationwide consultation on vape packaging, appearance and retail displays, proposing tighter rules to reduce youth appeal while industry groups warn of significant compliance costs.
Innovation
Jul.20
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Philip Morris Japan (PMJ) has expanded the ZYN by IQOS oral tobacco pouch portfolio in Japan with four new ZYN Strong products, adding a third intensity level alongside the existing Low and Medium ranges. The Strong series first entered selected duty-free channels in Japan on July 1, 2026, before expanding to IQOS stores, the ZYN Online Store and selected tobacco retailers from August 18. The expansion increases the Japanese ZYN by IQOS lineup from eight to 12 products.
Aug.20
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03